Rituximab Preferentially Eliminates BCR Signaling Proficient Chronic Lymphocytic Leukemia B Cells in Vivo

Gabriela Pavlasova,Marek Borsky,Katerina Musilova,Vaclav Seda,Katerina Cerna,Jitka Osickova,Eva Vojackova,Yvona Brychtova,Michael Doubek,Sarka Pospisilova,Jiri Mayer,Marek Mraz

Blood（2016）SCI 1区

CEITEC MU | Univ Hosp Brno

Cited 0|Views53

Abstract

The use of anti-CD20 antibody rituximab has significantly improved the outcome of patients with chronic lymphocytic leukemia (CLL). Rituximab has been shown to act through several mechanisms including antibody-dependent cell cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct induction of apoptosis, and sensitization to chemotherapy. However, the exact contribution of each of these mechanisms to the clinical efficacy of rituximab in vivo and the exact mechanism of its action remain unclear. Importantly, the levels of cell surface CD20 expression were shown to associate with the efficacy of rituximab.

Translated text

求助PDF

上传PDF

Bibtex

AI Read Science

AI Summary

AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.

Example

Background

Key content

Introduction

Methods

Results

Related work

Fund

Key content

Pretraining has recently greatly promoted the development of natural language processing (NLP)
We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance

Upload PDF to Generate Summary

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Chat Paper

【要点】：论文研究了抗CD20抗体利妥昔单抗在体内对慢性淋巴细胞白血病（CLL）细胞的作用机制，发现其优先消除BCR信号传导能力较强的CLL细胞，并探讨了其疗效与CD20表达水平的关系。

【方法】：作者通过分析利妥昔单抗的作用机制，包括抗体依赖性细胞毒性（ADCC）、补体依赖性细胞毒性（CDC）、直接诱导凋亡以及增加化疗敏感性，来研究其在CLL治疗中的效果。

【实验】：实验具体操作未详细描述，但研究了利妥昔单抗在不同CD20表达水平的CLL细胞上的作用，实验使用了相关细胞系和/或患者样本，结果揭示了利妥昔单抗对BCR信号传导能力较强的CLL细胞的优先消除作用，具体数据集名称未提及。